5-Amino-1MQ
Also known as: 5-Amino-1-methylquinolinium, NNMT inhibitor
Overview
5-Amino-1MQ is a small-molecule methylquinolinium derivative that functions as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes NAD+ precursors and regulates cellular energy metabolism. While technically a small molecule rather than a classical peptide, it is often discussed alongside peptide therapies due to its metabolic effects. By blocking NNMT, it prevents wasteful methylation of nicotinamide, preserving NAD+ availability and activating longevity-associated pathways.
Mechanism of Action
5-Amino-1MQ inhibits NNMT, the enzyme that methylates nicotinamide (a NAD+ breakdown product) using S-adenosylmethionine (SAM). NNMT overactivity in aging and obesity drains both NAD+ precursors and methyl groups. Inhibition leads to: 1.2-1.6 fold increase in cellular NAD+ in adipocytes; SIRT1 activation (the 'longevity gene') through greater NAD+ availability; white-to-brown adipose tissue conversion (beige adipogenesis) via histone methylation changes; AMPK-related pathway activation mimicking caloric restriction; and improved mitochondrial efficiency and muscle endurance in aged mice.
Potential Benefits
- NAD+ preservation and elevation (1.2-1.6 fold in preclinical models)
- Reversal of diet-induced obesity in mouse models
- Promotion of beige/brown fat conversion enhancing thermogenesis
- SIRT1 activation supporting longevity-associated gene programs
- Improved muscle endurance and recovery in aged mice
- Reduction of insulin resistance and adipose inflammation
- Synergistic with NAD+ precursor therapy (NMN, NR) for sustained effects
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 50-200 mg/day oral |
| Beginner | 50 mg/day |
| Intermediate | 100-150 mg/day |
| Advanced | 200 mg/day |
| Cycle Duration | 4-8 weeks |
| Cycle Off | 4 weeks |
5-Amino-1MQ is an oral small molecule NNMT inhibitor. Very early-stage experimental compound with limited human data. Dosing is extrapolated from preclinical models. Weight-based dosing from mouse studies suggests ~50 mg/day as human starting dose equivalent.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral (Capsule/Tablet) Varies — typically moderate for oral-stable compounds
Take with or without food as specified. Follow product labeling for timing.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving 5-Amino-1MQ:
Metabolic Health Stack
Combines 5-Amino-1MQ with MOTS-c (mitochondrial metabolism) and AOD-9604 (lipolysis) for metabolic optimization.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | N/A — oral capsules or powder |
|---|---|
| BAC Water | N/A — oral formulation |
| Storage | Store at room temperature 15-25°C; protect from moisture and light |
| Shelf Life | 24 months sealed |
Need exact syringe measurements?
Amino Acid Sequence
N/A (small molecule: C10H10N2)
Side Effects & Safety
- Limited human safety data
- Theoretical epigenetic effects from altered SAM availability
- Possible interactions with methylation-dependent pathways
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~6-8 hours (oral) |
|---|---|
| Storage | Store at room temperature (15-25°C) in a dry, dark place. Keep tightly closed. Do not refrigerate capsules. |
Synergistic Compounds
The following compounds have been studied alongside 5-Amino-1MQ for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.